EUVIMEDEUVIMED entdecken
Leserbrief

Chemoradiotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer

Dun-Chang Mo iD, Shang-Xiao Huang, Jian-Feng Huang iD, Xiu-Juan Liang, Han-Lei Wang

Journal of Clinical Oncology · 10.07.2026 · 44 (20) · 1949-1950

DOI: 10.1200/jco-25-02085 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.07.2026. Verfasst von Dun-Chang Mo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Dun-Chang Mo, MD; Shang-Xiao Huang, MD; Jian-Feng Huang, MD; Xiu-Juan Liang, MD; and Han-Lei Wang, MD, Radiotherapy Department, The Third Affiliated …. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 5 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Dun-Chang Mo, MD; Shang-Xiao Huang, MD; Jian-Feng Huang, MD; Xiu-Juan Liang, MD; and Han-Lei Wang, MD, Radiotherapy Department, The Third Affiliated Hospital of Guangxi Medical University, Nanning, China.

ORCID-Profile: Dun-Chang Mo, Jian-Feng Huang

Zitieren

APA

Mo, D. C., Huang, S. X., Huang, J. F., Liang, X. J., & Wang, H. L. (2026). Chemoradiotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer. Journal of Clinical Oncology, 44(20), 1949-1950. https://doi.org/10.1200/jco-25-02085

Vancouver

Mo DC, Huang SX, Huang JF, Liang XJ, Wang HL. Chemoradiotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer. Journal of Clinical Oncology. 2026;44(20):1949-1950. doi:10.1200/jco-25-02085

BibTeX
@article{Mo2026,
  author = {Mo, Dun-Chang and Huang, Shang-Xiao and Huang, Jian-Feng and Liang, Xiu-Juan and Wang, Han-Lei},
  title = {Chemoradiotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {20},
  pages = {1949--1950},
  doi = {10.1200/jco-25-02085}
}
Kostenlos starten →